Related Experiment Video
Updated: Nov 20, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
In silico approach of modified melanoma peptides and their immunotherapeutic potential
A C L Pereira1, K S Bezerra1, J L S Santos1
1Departamento de Biofísica e Farmacologia, Universidade Federal do Rio Grande do Norte, 59072-970, Natal-RN, Brazil. umbertofulco@gmail.com.
Abstract:
Melanoma is a type of skin cancer with increasing incidence worldwide and high lethality. Conventional forms of treatment are not effective in advanced cancer stages. Hence, immunotherapeutic approaches have been tested to modulate immune response against tumor cells. Some vaccine models using tumor-associated antigens (TAAs) such as glycoprotein 100 (gp100) have been studied, but their expected effectiveness has not been shown until now. Antigen immunogenicity is a crucial point to improve the immune response, and therefore mutations are inserted in peptide sequences. It is possible to understand the interactions which occur between peptides and immune system molecules through computer simulation, and this is essential in order to guide efficient vaccine models. In this work, we have calculated the interaction binding energies of crystallographic data based on modified gp100 peptides and HLA-A*0201 using density functional theory (DFT) and the molecular fractionation with conjugated caps (MFCC) approach. Our results show the most relevant residue-residue interactions, the impact of three mutations in their binding sites, and the main HLA-A*0201 amino acids for peptide-HLA binding.
Insights
This study used computational methods to analyze modified melanoma antigen gp100 peptides interacting with HLA-A*0201. The findings reveal key interactions and mutation impacts to guide the development of more effective cancer vaccines.
Area of Science:
- Computational chemistry
- Immunology
- Oncology
Background:
- Melanoma incidence and lethality are increasing globally.
- Conventional treatments are ineffective for advanced melanoma.
- Immunotherapy, including tumor-associated antigen (TAA) vaccines, shows promise but requires optimization.
Purpose of the Study:
- To computationally investigate the binding interactions of modified gp100 peptides with HLA-A*0201.
- To identify key residue interactions and the impact of specific mutations on peptide-HLA binding.
- To guide the design of more immunogenic and effective melanoma vaccines.
Main Methods:
- Density Functional Theory (DFT) calculations.
- Molecular Fractionation with Conjugated Caps (MFCC) approach.
- Analysis of crystallographic data for modified gp100 peptides and HLA-A*0201.
Main Results:
- Identified critical residue-residue interactions between modified gp100 peptides and HLA-A*0201.
- Quantified the impact of three specific mutations on peptide-HLA binding energies.
- Determined the primary amino acid residues of HLA-A*0201 involved in peptide binding.
Conclusions:
- Computational simulations provide insights into peptide-HLA interactions for vaccine design.
- Understanding these interactions is crucial for enhancing antigen immunogenicity.
- The study offers a computational framework to guide the development of improved melanoma immunotherapies.
More Related Videos
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
